Clinical Trials
3 trialsNCT06692452 2026-04-01
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT03629873 2022-01-03
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated